The Latest Updates from ReSPECT Clinical Trials
Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care
Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care At Plus Therapeutics, our mission is clear: to address some of the toughest challenges in oncology by improving the efficacy, precision, and convenience of modern radiotherapeutic treatments....
FDA Clears IND for Plus Therapeutics’ REYOBIQ™ in Pediatric Brain Cancer Trial
FDA Clears IND for Plus Therapeutics' REYOBIQ™ in Pediatric Brain Cancer Trial Plus Therapeutics is pleased to announce that the U.S. Food and Drug Administration (FDA) has officially cleared its Investigational New Drug (IND) application for REYOBIQ™, a targeted...
Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News
Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News Andrew Brenner, M.D., Ph.D., one of Plus Therapeutics’ Principal Investigators for the RESPECT-GBM clinical trial, recently appeared on KABB News with Melissa Vega to discuss the ongoing battle...
Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial
Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial As part of our ongoing commitment to highlight the incredible medical professionals behind the ReSPECT-GBM clinical trial, today we are proud to...
Honoring Brain Tumor Awareness Day: Supporting Glioblastoma Patients Through Advocacy and Innovation
Honoring Brain Tumor Awareness Day: Supporting Glioblastoma Patients Through Advocacy and Innovation Today is Brain Tumor Awareness Day—a day dedicated to raising awareness for those affected by brain tumors and honoring the patients, caregivers, and advocates working...
June Is Brain and Spine Metastasis Awareness Month: Spotlight on Leptomeningeal Metastases and New Treatment Approaches
June Is Brain and Spine Metastasis Awareness Month: Spotlight on Leptomeningeal Metastases and New Treatment Approaches Following Brain Cancer Awareness Month, June marks Brain and Spine Metastasis Awareness Month, a critical time to raise awareness about the...
New Coverage: Rhenium Obisbemeda Shows Promise in Recurrent Glioblastoma – Q&A with Dr. Andrew Brenner
New Coverage: Rhenium Obisbemeda Shows Promise in Recurrent Glioblastoma – Q&A with Dr. Andrew Brenner A new article by Ariana Pelosci at Cancer Network highlights promising data from Plus Therapeutics’ ongoing Phase 1/2 ReSPECT-GBM clinical trial, which is...
Honoring National Gray Day: Advancing Brain Cancer Awareness and Research
Honoring National Gray Day: Advancing Brain Cancer Awareness and Research Today marks National Gray Day, a powerful observance during Brain Cancer Awareness Month dedicated to honoring the lives lost to brain cancer and standing in solidarity with patients, survivors,...
Advancing CNS Cancer Treatment: Plus Therapeutics CEO Talks Radiotherapeutics on Xtalks Podcast
Advancing CNS Cancer Treatment: Plus Therapeutics CEO Talks Radiotherapeutics on Xtalks Podcast In case you missed it, Plus Therapeutics President and CEO Dr. Marc Hedrick recently joined Ayesha Rashid on the Xtalks Life Sciences Podcast to discuss the company’s...
NMN Symposium 2025
New Data on REYOBIQ™ for Leptomeningeal Metastases Presented at the NMN Conference! Plus Therapeutics is pleased to announce that new clinical data on its lead investigational therapy, REYOBIQ™ (rhenium Re 186 obisbemeda), was presented at the Nuclear Medicine and...
Brain Cancer Awareness Month 2025
Honoring Brain Cancer Awareness Month: Advancing Research, Raising Voices, and Recruiting for Clinical Trials May is Brain Cancer Awareness Month! A time dedicated to elevating the voices of patients, caregivers, and advocates affected by brain tumors. At Plus...
“A New Way to Treat Brain Cancer?”
REYOBIQ™ Clinical Trial for Recurrent Glioma Featured in Oncolytics Today We’re proud to share that Plus Therapeutics’ innovative work on REYOBIQ™ (rhenium-186 Re obisbemeda) has been featured as the cover story in the latest issue of Oncolytics Today, published by...
NMN 2025 Abstract Announcement
Plus Therapeutics to Present New REYOBIQ™ Clinical Data at Nuclear Medicine Symposium 2025 We’re excited to announce that Plus Therapeutics will present new data on our lead radiotherapeutic compound, REYOBIQ™ (rhenium Re186 obisbemeda), at the upcoming Nuclear...
About Radiotherapeutics: Solutions for Rare Cancers
Advancing Radiotherapeutic Solutions for Rare Cancers At Plus Therapeutics, our mission is clear: to develop safe, effective, and lasting solutions for patients facing rare and hard-to-treat cancers. Every day, our dedicated team works alongside clinicians and...
About Radiotherapeutics: Radionuclide-Based Therapies
The Power of Radionuclide-Based Therapies in Modern Cancer Treatment Radionuclide-based therapies represent a rapidly evolving frontier in precision oncology, offering targeted treatment options for a wide range of cancer types. These therapies utilize radionuclides...
About Radiotherapeutics: Advancing Technology
A Novel Radiotherapeutic Platform Targeting Complex Tumors with Precision At Plus Therapeutics, we’re pioneering a next-generation radiotherapeutic platform designed to deliver targeted cancer treatment with high precision and minimal toxicity. Our platform is powered...
REYOBIQ™: The Future of CNS Cancer Care
REYOBIQ™: A Promising Radiotherapeutic Advancing Treatment for Glioblastoma, Leptomeningeal Metastases, and Pediatric Brain Cancers At Plus Therapeutics, we’re advancing the future of cancer care with REYOBIQ™ (rhenium-186 Re obisbemeda), our lead targeted...
Advancing Treatment for Pediatric Brain Cancer
ReSPECT-PBC Clinical Trial: Advancing Treatment for Pediatric Brain Cancer Pediatric brain tumors are among the leading causes of cancer-related deaths in children, with limited treatment options for aggressive tumors like ependymoma and high-grade glioma (HGG). The...
Introducing REYOBIQ™
Introducing REYOBIQ™: The FDA-Accepted Proprietary Name for Plus Therapeutics’ Lead Drug Candidate Big News from Plus Therapeutics! The U.S. Food and Drug Administration (FDA) has conditionally accepted the proprietary name REYOBIQ™ (rhenium Re186 obisbemeda) for our...
Advancing Treatment for Leptomeningeal Metastases
Advancing Treatment for Leptomeningeal Metastases (LM): ReSPECT-LM Clinical Trial Now Enrolling Leptomeningeal metastases (LM) is a devastating complication of cancer, occurring when malignant cells spread to the cerebrospinal fluid (CSF) and leptomeninges, leading to...
Contents
- 1 The Latest Updates from ReSPECT Clinical Trials
- 1.1 Plus Therapeutics: Advancing the Future of Radiotherapeutics in Cancer Care
- 1.2 FDA Clears IND for Plus Therapeutics’ REYOBIQ™ in Pediatric Brain Cancer Trial
- 1.3 Dr. Andrew Brenner Discusses Glioblastoma and REYOBIQ™ on KABB News
- 1.4 Spotlight on Dr. Toral Patel: Leading Brain Tumor Surgeon and Principal Investigator in the ReSPECT-GBM Clinical Trial
- 1.5 Honoring Brain Tumor Awareness Day: Supporting Glioblastoma Patients Through Advocacy and Innovation
- 1.6 June Is Brain and Spine Metastasis Awareness Month: Spotlight on Leptomeningeal Metastases and New Treatment Approaches
- 1.7 New Coverage: Rhenium Obisbemeda Shows Promise in Recurrent Glioblastoma – Q&A with Dr. Andrew Brenner
- 1.8 Honoring National Gray Day: Advancing Brain Cancer Awareness and Research
- 1.9 Advancing CNS Cancer Treatment: Plus Therapeutics CEO Talks Radiotherapeutics on Xtalks Podcast
- 1.10 NMN Symposium 2025
- 1.11 Brain Cancer Awareness Month 2025
- 1.12 “A New Way to Treat Brain Cancer?”
- 1.13 NMN 2025 Abstract Announcement
- 1.14 About Radiotherapeutics: Solutions for Rare Cancers
- 1.15 About Radiotherapeutics: Radionuclide-Based Therapies
- 1.16 About Radiotherapeutics: Advancing Technology
- 1.17 REYOBIQ™: The Future of CNS Cancer Care
- 1.18 Advancing Treatment for Pediatric Brain Cancer
- 1.19 Introducing REYOBIQ™
- 1.20 Advancing Treatment for Leptomeningeal Metastases